1. Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents

   • Valentin al Jalali
   • Markus Zeitlinger

   Review Article Open access 26 February 2020 Pages: 827 - 847

   

2. Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib

   • Dominique Levêque
   • Guillaume Becker
   • Shanti Natarajan-Amé

   Review Article 29 February 2020 Pages: 849 - 856

3. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications

   • Amina Bensalem
   • David Ternant

   Review Article 13 March 2020 Pages: 857 - 874

   

4. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

   • Aurelia H. M. de Vries Schultink
   • Kees Bol
   • Alwin D. R. Huitema

   Original Research Article 31 January 2020 Pages: 875 - 884

   

5. Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate

   • Femke de Velde
   • Brenda C. M. de Winter
   • COMBACTE-NET consortium

   Original Research Article Open access 20 January 2020 Pages: 885 - 898

   

6. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis

   • Ruben van der Galiën
   • Natasha van’t Boveneind-Vrubleuskaya
   • Jan-Willem C. Alffenaar

   Original Research Article 25 January 2020 Pages: 899 - 910

   

7. Integration of Placental Transfer in a Fetal–Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus

   • Paola Mian
   • Karel Allegaert
   • André Dallmann

   Original Research Article Open access 12 February 2020 Pages: 911 - 925

   

8. Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial

   • Manuela Vay
   • Marleen Julia Meyer
   • Gerd Mikus

   Original Research Article Open access 15 February 2020 Pages: 927 - 939

   

9. Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients

   • Stefanie L. Groenland
   • Ruben A. G. van Eerden
   • The Dutch Pharmacology Oncology Group (DPOG)

   Original Research Article 04 February 2020 Pages: 941 - 948